You are requesting information on: Tasrif Pharmaceutical Granted Second US Patent For CD155-Targeting Antibody Developed With Abzena's Humanization Immunogenicity Platforms Abzena
Already a member of Outsourced Pharma or VertMarkets? Sign in now.
In order for our suppliers to better serve your request, please enter specific requirements or questions below: